Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas.

Liu TJ, Koul D, LaFortune T, Tiao N, Shen RJ, Maira SM, Garcia-Echevrria C, Yung WK.

Mol Cancer Ther. 2009 Aug;8(8):2204-10. doi: 10.1158/1535-7163.MCT-09-0160. Epub 2009 Aug 11.

2.

In search of an "autophagomometer".

Rubinsztein DC, Cuervo AM, Ravikumar B, Sarkar S, Korolchuk V, Kaushik S, Klionsky DJ.

Autophagy. 2009 Jul;5(5):585-9. Epub 2009 Jul 23.

PMID:
19411822
3.

Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR).

García-Martínez JM, Moran J, Clarke RG, Gray A, Cosulich SC, Chresta CM, Alessi DR.

Biochem J. 2009 Jun 12;421(1):29-42. doi: 10.1042/BJ20090489.

4.

Molecular mechanisms of mTOR-mediated translational control.

Ma XM, Blenis J.

Nat Rev Mol Cell Biol. 2009 May;10(5):307-18. doi: 10.1038/nrm2672. Epub 2009 Apr 2. Review.

PMID:
19339977
5.

Regulation of phosphoinositide 3-kinase expression in health and disease.

Kok K, Geering B, Vanhaesebroeck B.

Trends Biochem Sci. 2009 Mar;34(3):115-27. doi: 10.1016/j.tibs.2009.01.003. Epub 2009 Mar 18. Review.

PMID:
19299143
6.

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.

Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D, Shokat KM.

PLoS Biol. 2009 Feb 10;7(2):e38. doi: 10.1371/journal.pbio.1000038.

7.

EGFR signals to mTOR through PKC and independently of Akt in glioma.

Fan QW, Cheng C, Knight ZA, Haas-Kogan D, Stokoe D, James CD, McCormick F, Shokat KM, Weiss WA.

Sci Signal. 2009 Jan 27;2(55):ra4. doi: 10.1126/scisignal.2000014. Erratum in: Sci Signal. 2009;2(60):er4.

8.

An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1.

Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, Reichling LJ, Sim T, Sabatini DM, Gray NS.

J Biol Chem. 2009 Mar 20;284(12):8023-32. doi: 10.1074/jbc.M900301200. Epub 2009 Jan 15.

9.

Inhibition of autophagy by 3-MA enhances the effect of 5-FU-induced apoptosis in colon cancer cells.

Li J, Hou N, Faried A, Tsutsumi S, Takeuchi T, Kuwano H.

Ann Surg Oncol. 2009 Mar;16(3):761-71. doi: 10.1245/s10434-008-0260-0. Epub 2008 Dec 31.

PMID:
19116755
10.

PI3K signaling in glioma--animal models and therapeutic challenges.

Cheng CK, Fan QW, Weiss WA.

Brain Pathol. 2009 Jan;19(1):112-20. doi: 10.1111/j.1750-3639.2008.00233.x. Review.

11.

Inhibition of autophagy at a late stage enhances imatinib-induced cytotoxicity in human malignant glioma cells.

Shingu T, Fujiwara K, Bögler O, Akiyama Y, Moritake K, Shinojima N, Tamada Y, Yokoyama T, Kondo S.

Int J Cancer. 2009 Mar 1;124(5):1060-71. doi: 10.1002/ijc.24030.

12.

Autophagic cell death: the story of a misnomer.

Kroemer G, Levine B.

Nat Rev Mol Cell Biol. 2008 Dec;9(12):1004-10. doi: 10.1038/nrm2529. Epub 2008 Oct 30. Review.

13.

Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009.

Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke EH, Blagosklonny MV, El-Deiry WS, Golstein P, Green DR, Hengartner M, Knight RA, Kumar S, Lipton SA, Malorni W, Nuñez G, Peter ME, Tschopp J, Yuan J, Piacentini M, Zhivotovsky B, Melino G; Nomenclature Committee on Cell Death 2009.

Cell Death Differ. 2009 Jan;16(1):3-11. doi: 10.1038/cdd.2008.150. Epub 2008 Oct 10.

14.

Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents.

Degtyarev M, De Mazière A, Orr C, Lin J, Lee BB, Tien JY, Prior WW, van Dijk S, Wu H, Gray DC, Davis DP, Stern HM, Murray LJ, Hoeflich KP, Klumperman J, Friedman LS, Lin K.

J Cell Biol. 2008 Oct 6;183(1):101-16. doi: 10.1083/jcb.200801099.

15.

Comprehensive genomic characterization defines human glioblastoma genes and core pathways.

Cancer Genome Atlas Research Network.

Nature. 2008 Oct 23;455(7216):1061-8. doi: 10.1038/nature07385. Epub 2008 Sep 4. Erratum in: Nature. 2013 Feb 28;494(7438):506.

16.

An integrated genomic analysis of human glioblastoma multiforme.

Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW.

Science. 2008 Sep 26;321(5897):1807-12. doi: 10.1126/science.1164382. Epub 2008 Sep 4.

17.

PTEN and the PI3-kinase pathway in cancer.

Chalhoub N, Baker SJ.

Annu Rev Pathol. 2009;4:127-50. doi: 10.1146/annurev.pathol.4.110807.092311. Review.

18.

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.

Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chène P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, García-Echeverría C.

Mol Cancer Ther. 2008 Jul;7(7):1851-63. doi: 10.1158/1535-7163.MCT-08-0017. Epub 2008 Jul 7.

19.

UVA-induced cell cycle progression is mediated by a disintegrin and metalloprotease/epidermal growth factor receptor/AKT/Cyclin D1 pathways in keratinocytes.

He YY, Council SE, Feng L, Chignell CF.

Cancer Res. 2008 May 15;68(10):3752-8. doi: 10.1158/0008-5472.CAN-07-6138.

20.

Blocked autophagy sensitizes resistant carcinoma cells to radiation therapy.

Apel A, Herr I, Schwarz H, Rodemann HP, Mayer A.

Cancer Res. 2008 Mar 1;68(5):1485-94. doi: 10.1158/0008-5472.CAN-07-0562.

Supplemental Content

Support Center